This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi's (SNY) Dupixent sBLA for Asthma Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Sanofi's (SNY) sBLA for review of Dupixent for treating moderate-to-severe asthma in children aged six-11 years. A verdict from the FDA is expected on Oct 21, 2021.
Top Stock Reports for Johnson & Johnson, UnitedHealth & Comcast
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), and Comcast (CMCSA).
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition
by Kinjel Shah
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout
by Kinjel Shah
Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion
Moderna (MRNA) Misses on Q4 Earnings, Eyes $18B in Vaccine Sales
by Zacks Equity Research
Moderna (MRNA) records product sales for the first time which comprises sales of its coronavirus vaccine, mRNA-1273. Stock up.
Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates
by Zacks Equity Research
Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.
Emergent (EBS) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.
Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day
Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ
by Kinjel Shah
WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.
Is a Beat in Store for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.
Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.
J&J (JNJ) Seeks Conditional Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
J&J's (JNJ) COVID-19 vaccine, if approved, will be the only COVID-19 vaccine to be approved for single administration.
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.
J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.
Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates
by Kinjel Shah
Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.
Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.
Merck (MRK) Q4 Earnings & Sales Miss, CEO Frazier Steps Down
by Zacks Equity Research
Merck (MRK) misses Q4 estimates for earnings and sales. CEO Kenneth C. Frazier, to retire.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $50, marking a -0.12% move from the previous day.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.